159 related articles for article (PubMed ID: 38605220)
1. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Hepatocellular Carcinoma Treated with Conventional Transcatheter Arterial Chemoembolization: A Propensity Score Matched Analysis.
Deng Z; Zhang W; Peng J; Gao L; Zhang C; Lei K; Gong J; Xiong B
Cardiovasc Intervent Radiol; 2024 May; 47(5):592-603. PubMed ID: 38605220
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
3. Nomograms including the controlling nutritional status score in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation for prediction survival: a retrospective analysis.
Chen Y; Xu WJ; Yang Y; Xin YJ; Zhang XY; Li X; Zhou X
Br J Nutr; 2022 Nov; 128(10):1966-1974. PubMed ID: 34881693
[TBL] [Abstract][Full Text] [Related]
4. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
[TBL] [Abstract][Full Text] [Related]
5. Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with HBV-associated hepatocellular carcinoma after curative hepatectomy.
Lin ZX; Ruan DY; Jia CC; Wang TT; Cheng JT; Huang HQ; Wu XY
Clin Transl Oncol; 2020 Mar; 22(3):370-380. PubMed ID: 31201606
[TBL] [Abstract][Full Text] [Related]
6. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
[TBL] [Abstract][Full Text] [Related]
7. Postoperative controlling nutritional status score is an independent risk factor of survival for patients with small hepatocellular carcinoma: a retrospective study.
Peng W; Yao M; Zou K; Li C; Wen T; Sun X
BMC Surg; 2021 Sep; 21(1):338. PubMed ID: 34493254
[TBL] [Abstract][Full Text] [Related]
8. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
9. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.
Chen S; Shi M; Shen L; Qi H; Wan W; Cao F; Xie L; Wu Y; Chen G; Mo J; Zhu G; Ye D; Zhang Y; Feng Z; Xu L; Fan W
Int J Hyperthermia; 2020; 37(1):384-391. PubMed ID: 32323585
[No Abstract] [Full Text] [Related]
10. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis.
Yang Y; Lin K; Liu L; Qian Y; Yang Y; Yuan S; Zhu P; Huang J; Liu F; Gu F; Fu S; Jiang B; Liu H; Pan Z; Lau WY; Zhou W
Cancer Med; 2021 Mar; 10(6):2100-2111. PubMed ID: 33650288
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma.
Chen MY; Juengpanich S; Hu JH; Topatana W; Cao JS; Tong CH; Lin J; Cai XJ
World J Gastroenterol; 2020 Mar; 26(10):1042-1055. PubMed ID: 32205995
[TBL] [Abstract][Full Text] [Related]
12. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma.
Hao MZ; Lin HL; Chen QZ; Hu YB; Chen JB; Zheng JX; Zhou D; Zhang H
J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344
[TBL] [Abstract][Full Text] [Related]
14. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation.
Ginsburg M; Zivin SP; Wroblewski K; Doshi T; Vasnani RJ; Van Ha TG
J Vasc Interv Radiol; 2015 Mar; 26(3):330-41. PubMed ID: 25534635
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Combined Therapy Using Conventional Chemoembolization and Radiofrequency Ablation Versus Conventional Chemoembolization for Ultrasound-Invisible Early-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer Stage 0 or A).
Lee H; Yoon CJ; Seong NJ; Jeong SH; Kim JW
Korean J Radiol; 2018; 19(6):1130-1139. PubMed ID: 30386144
[TBL] [Abstract][Full Text] [Related]
16. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.
Li C; Wang MD; Lu L; Wu H; Yu JJ; Zhang WG; Pawlik TM; Zhang YM; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Xing H; Li ZL; Lau WY; Wu MC; Shen F; Yang T
Hepatol Int; 2019 Nov; 13(6):736-747. PubMed ID: 31486964
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of controlling nutritional status and skeletal muscle mass in patients with hepatocellular carcinoma after curative treatment.
Tamai Y; Iwasa M; Eguchi A; Shigefuku R; Sugimoto R; Tanaka H; Kobayashi Y; Mizuno S; Nakagawa H
Eur J Gastroenterol Hepatol; 2022 Dec; 34(12):1269-1276. PubMed ID: 36317773
[TBL] [Abstract][Full Text] [Related]
18. Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival.
Shimose S; Iwamoto H; Tanaka M; Niizeki T; Shirono T; Kajiwara A; Noda Y; Kamachi N; Okamura S; Nakano M; Kuromatsu R; Kawaguchi T; Koga H; Torimura T
Oncology; 2021; 99(12):756-765. PubMed ID: 34518483
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC
Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Study of Controlling Nutritional Status (CONUT) Score as a Prognostic Factor in Patients With HIV-Related Renal Cell Carcinoma.
Xue W; Zhang Y; Wang H; Zhang Y; Hu X
Front Immunol; 2021; 12():778746. PubMed ID: 34917092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
